Novo Nordisk Offers €2.6bn For Ablynx
Danish diabetes drug specialist Novo Nordisk has offered €2.6bn in cash to acquire Ablynx. The Belgian firm is playing hard to get: this is the second offer from Novo but it is still refusing to talk.
Danish diabetes drug specialist Novo Nordisk has offered €2.6bn in cash to acquire Ablynx. The Belgian firm is playing hard to get: this is the second offer from Novo but it is still refusing to talk.